Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19
Clinical and Experimental Immunology · 2024
DOI: 10.1093/cei/uxae047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Elena Woods und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Biochemistry and Immunology, Trinity Biomedical Research Institute, Trinity College Dublin, Dublin 2, Ireland. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Interleukins, Interferons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Foundation Ireland.
Abstract (Originalsprache)
The recent pandemic was caused by the emergence of a new human pathogen, SARS-CoV-2. While the rapid development of many vaccines provided an end to the immediate crisis, there remains an urgent need to understand more about this new virus and what constitutes a beneficial immune response in terms of successful resolution of infection. Indeed, this is key for development of vaccines that provide long lasting protective immunity. The interferon lambda (IFNL) family of cytokines are produced early in response to infection and are generally considered anti-viral and beneficial. However, data regarding production of IFNL cytokines in coronavirus disease 2019 (COVID-19) patients is highly variable, and generally from underpowered studies. In this study, we measured all three IFNL1, IFNL2, and IFNL3 cytokines in plasma from a well characterized, large COVID-19 cohort (n = 399) that included good representation from patients with a more indolent disease progression, and hence a beneficial immune response. While all three cytokines were produced, they differed in both the frequency of expression in patients, and the levels produced. IFNL3 was produced in almost all patients but neither protein level nor IFNL3/IFNL4 single nucleotide polymorphisms were associated with clinical outcome. In contrast, both IFNL1 and IFNL2 levels were significantly lower, or absent, in plasma of patients that had a more severe disease outcome. These data are consistent with the concept that early IFNL1 and IFNL2 cytokine production is protective against SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biochemistry and Immunology, Trinity Biomedical Research Institute, Trinity College Dublin, Dublin 2, Ireland.
- Institute for Infection and Immunity, St George's, University of London, Cranmer Terrace, London, UK.
- STTAR Bioresource, CRF, St. James's Hospital, Dublin, Ireland.
- National Histocompatibility and Immunogenetics Reference Laboratory, National Blood Centre, Dublin, Ireland.
- Department of Infectious Diseases, St. James's Hospital, Dublin, Ireland.
- School of Computer Science and Statistics, Trinity College Dublin, Dublin 2, Ireland.
ORCID-Profile: Clair M Gardiner
Förderung
- Science Foundation Ireland
Zitieren
APA
Woods, E., Mena, A., Sierpinska, S., Carr, E., Sttar Bioresource, Hagan, R., Crowley, J., Bergin, C., Clark, D., Brophy, C., Macallan, D., & Gardiner, C. M. (2024). Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxae047
Vancouver
Woods E, Mena A, Sierpinska S, Carr E, Sttar Bioresource, Hagan R, et al. Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxae047
BibTeX
@article{Woods2024,
author = {Woods, Elena and Mena, Adriana and Sierpinska, Sophie and Carr, Emily and Sttar Bioresource and Hagan, Richard and Crowley, John and Bergin, Colm and Clark, David and Brophy, Caroline and Macallan, Derek and Gardiner, Clair M},
title = {Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19},
journal = {Clinical and Experimental Immunology},
year = {2024},
doi = {10.1093/cei/uxae047}
}
EUVIMED